ERBB2 and triple-negative breast carcinoma: The efficacy of this approach has been shown in triple-negative breast cancer using anti-PEG x EGFR bsAbs [34], in HER2-positive breast adenocarcinoma with anti-HER2 x anti-mPEG bsAbs [35, 36], and in lymphoma with anti-CD20 x anti-mPEG bsAbs [37].